Background Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …

The heterogeneity of the immune microenvironment leads to different responses in immune
checkpoint blockade therapy. We aimed to propose a robust molecular classification system …

Purpose: Therapies targeting the programmed death 1 (PD-1)/programmed death ligand 1
(PD-L1) pathway promote anti-tumor immunity and have shown promising results in various …

BACKGROUND: Primary prostate cancers are infiltrated with programmed death-1 (PD-1)
expressing CD8+ T-cells. However, in early clinical trials, men with metastatic castrate …

Prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy are at
higher risk of tumor recurrence and receive immediate androgen deprivation therapy (ADT) …

One in seven men in North America is expected to be diagnosed with prostate cancer (PCa)
during their lifetime (,). While a wide range of treatment options including surgery, radiation …

Multiple studies have confirmed that programmed cell death 1/programmed cell death ligand-
1 (PD-1/PD-L1) and immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 play pivotal …

Background Advanced prostate cancer remains one of the most common and deadly
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …

Immunotherapy encompasses a wide range of therapies to engage the immune system to
target malignancies. In recent years, immunotherapy has made a major impact on treatment …

The landscape of cancer treatment has been transformed over the past decade by the
success of immune-targeting therapies. However, despite sipuleucel-T being the first-ever …